Norinchukin Bank The Has $26.29 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Norinchukin Bank The raised its stake in Eli Lilly and Company (NYSE:LLY) by 7.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 34,048 shares of the company’s stock after buying an additional 2,280 shares during the period. Norinchukin Bank The’s holdings in Eli Lilly and Company were worth $26,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the stock. Highline Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after buying an additional 20 shares in the last quarter. FPC Investment Advisory Inc. increased its position in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter worth about $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $58,000. 82.53% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $841.70 on Friday. The business has a 50 day moving average of $829.09 and a 200-day moving average of $820.35. The company has a market capitalization of $798.08 billion, a P/E ratio of 71.88, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LLY. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Morgan Stanley reduced their target price on Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating on the stock in a report on Wednesday, April 9th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research note on Thursday, January 16th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Guggenheim decreased their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.